The ultimate resource on the IRA
On August 16, 2022, President Joe Biden signed the Inflation Reduction Act (IRA) into law. Significant changes are coming regarding drug pricing and payment in the United States. There are a number of implications that biopharma companies will need to consider across the full drug discovery, development, and commercialization spectrum as they adapt to this U.S. marketplace reality.
Explore our insights and perspectives on the key elements of the new law and tap into our comprehensive understanding of the IRA. Contact us to start a conversation and our health policy and government affairs experts can guide you to the right solutions to help you navigate the IRA.
Article
The unintended consequences of the Inflation Reduction Act (IRA)
Article
Diagnosing the health (policy) of our nation: The impact of November’s elections
As the US November general election results unfold, healthcare stakeholders are keen to understand their implications for federal health policy. This article highlights key takeaways on how the evolving political landscape will impact market access, regulatory priorities, and patient outcomes, offering strategies to prepare for these changes.
Connect with our global consulting services experts
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
Our extensive portfolio of solutions includes:
- Consulting services
- Pharmacovigilance
- Regulatory affairs
- Commercialization
- Quality management compliance
- Real world evidence
- Global health economics & outcome research (HEOR)
- Trial Master File (TMF)
Pardot Form